Cargando…

Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide

AIMS/INTRODUCTION: To investigate the efficacy and safety of vildagliptin, a potent dipeptidyl peptidase‐4 inhibitor, as add‐on to nateglinide, compared with switching to vildagliptin in Japanese type 2 diabetes patients poorly controlled with nateglinide. MATERIALS AND METHODS: A total of 40 patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kudo‐Fujimaki, Kyoko, Hirose, Takahisa, Yoshihara, Tomoaki, Sato, Fumihiko, Someya, Yuki, Ohmura, Chie, Kanazawa, Akio, Fujitani, Yoshio, Watada, Hirotaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley-Blackwell 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210064/ https://www.ncbi.nlm.nih.gov/pubmed/25411599 http://dx.doi.org/10.1111/jdi.12160

Ejemplares similares

Comparison of sitagliptin with nateglinide on postprandial glucose and related hormones in drug-naïve Japanese patients with type 2 diabetes mellitus: A pilot study
por: Tanimoto, Masumi, et al.
Publicado: (2015)

Efficacy and Safety of Vildagliptin as an Add-On Therapy in Inadequately Controlled Type 2 Diabetes Patients Treated With Basal Insulin
por: Saito, Daisuke, et al.
Publicado: (2017)

A review of nateglinide in the management of patients with type 2 diabetes
por: Tentolouris, Nicholas, et al.
Publicado: (2007)

Development and validation of analytical method for the estimation of nateglinide in rabbit plasma
por: Pani, Nihar Ranjan, et al.
Publicado: (2012)

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021)

Effects of Glucose Load and Nateglinide Intervention on Endothelial Function and Oxidative Stress
por: Wang, Leilei, et al.
Publicado: (2013)

Glucose-dependent and Glucose-sensitizing Insulinotropic Effect of Nateglinide: Comparison to Sulfonylureas and Repaglinide
por: Hu, Shiling, et al.
Publicado: (2001)

Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes
por: Israel, Marc K, et al.
Publicado: (2008)

The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus
por: Guardado-Mendoza, Rodolfo, et al.
Publicado: (2013)

Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone
por: Ristic, S, et al.
Publicado: (2006)

Morningness–eveningness questionnaire score correlates with glycated hemoglobin in middle‐aged male workers with type 2 diabetes mellitus
por: Iwasaki, Masato, et al.
Publicado: (2013)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

Surfing the Vildagliptin Tsunami
por: Balachandran, Karthik
Publicado: (2020)

Effectiveness of Nateglinide on In Vitro Insulin Secretion from Rat Pancreatic Islets Desensitized to Sulfonylureas
por: Hu, Shiling, et al.
Publicado: (2001)

Simultaneous Determination of Metformin, Nateglinide and Gliclazide in Pharmaceutical Preparations Using Micellar Liquid Chromatography
por: El-Wasseef, Dalia Rashad
Publicado: (2012)

Formulation and In Vitro Evaluation of Bilayer Tablets of Nebivolol Hydrochloride and Nateglinide for the Treatment of Diabetes and Hypertension
por: Ryakala, Harika, et al.
Publicado: (2015)

Development and in vitro/in vivo evaluation of controlled release provesicles of a nateglinide–maltodextrin complex
por: Sahoo, Ranjan Ku., et al.
Publicado: (2014)

Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus
por: Kawamori, Ryuzo, et al.
Publicado: (2012)

Helical‐Like Assembly of Nateglinide as Coating for Oral Delivery of Insulin and Their Synergistic Prevention of Diabetes Mellitus
por: Li, Yanfei, et al.
Publicado: (2023)

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
por: Kim, Jong Ho, et al.
Publicado: (2016)

Effect of Vildagliptin on Hepatic Steatosis
por: Macauley, Mavin, et al.
Publicado: (2015)

Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study
por: Kato, Toru, et al.
Publicado: (2010)

Characterization of binding by repaglinide and nateglinide with glycated human serum albumin using high‐performance affinity microcolumns
por: Ovbude, Susan T., et al.
Publicado: (2022)

Mild acute pancreatitis with vildagliptin use
por: Saraogi, Ravikant, et al.
Publicado: (2012)

Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
por: Wiciński, Michał, et al.
Publicado: (2020)

Nateglinide is Effective for Diabetes Mellitus with Reactive Hypoglycemia in a Child with a Compound Heterozygous ABCC8 Mutation
por: Saito-Hakoda, Akiko, et al.
Publicado: (2012)

Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.K
por: Ward, Alexandra J, et al.
Publicado: (2004)

A case of vildagliptin-induced interstitial pneumonia
por: Kuse, Naoyuki, et al.
Publicado: (2016)

Physicochemical Properties and Methods of Analysis of Vildagliptin (Review)
por: Polyakova, E. B., et al.
Publicado: (2022)

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea
por: Lukashevich, V, et al.
Publicado: (2014)

Vildagliptin efficacy in combination with metformin among Jordanian patients with type 2 diabetes mellitus inadequately controlled with metformin
por: Al Omari, Mousa, et al.
Publicado: (2016)

Combination of the Framingham Risk Score and Carotid Intima-Media Thickness Improves the Prediction of Cardiovascular Events in Patients With Type 2 Diabetes
por: Yoshida, Michiko, et al.
Publicado: (2012)

Repaglinide, but Not Nateglinide Administered Supraspinally and Spinally Exerts an Anti-Diabetic Action in D-Glucose Fed and Streptozotocin-Treated Mouse Models
por: Sim, Yun-Beom, et al.
Publicado: (2013)

Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers
por: Schnaars, Yvonne, et al.
Publicado: (2022)

Efficacy of pioglitazone on glycemic control and carotid intima‐media thickness in type 2 diabetes patients with inadequate insulin therapy
por: Yasunari, Eisuke, et al.
Publicado: (2011)

The Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes
por: Moon, Jun Sung, et al.
Publicado: (2013)

Vildagliptin/metformin: Lactic acidosis and hypoglycaemia: case report
Publicado: (2022)

Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study
por: Van Gaal, Luc, et al.
Publicado: (2019)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2012)

Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus
por: Ved, Paresh, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_u97f8788m3s145aj7pj19sae6v